Results 131 to 140 of about 63,602 (218)

Cost-effectiveness of cabozantinib versus placebo for advanced neuroendocrine tumors from crossover-adjusted analysis in the United States and China. [PDF]

Sci Rep
Lang W, Huang B, Zhang G, Deng L, Lu H, Lu M, Pan Y.   +6 more
europepmc   +1 more source

[003]ICER Newsletter

[003]ICER Newsletter
新しい教材を体験しませんか？インタラクティブな教材開発に利用できる新技術紹介 / ビブリオバトル:九州大学 21世紀プログラム 決勝 / スマートフォンやタブレットに授業資料を配布！ / 知っていますか？電子教材の著作権 / これからの講習会開催予定 / 講義などの教育コンテンツを撮影しませんか？
openaire  

The cost-effectiveness of using vilobelimab with immunomodulators to treat severely ill mechanically ventilated patients with COVID-19: A subgroup analysis of the PANAMO study. [PDF]

Am J Health Syst Pharm
Malone DC, Seheult R, Brixner D, Oderda G, Burnett BP, Biskupiak J.   +5 more
europepmc   +1 more source

Cost-utility analysis of the Circle of Security-Parenting programme to reduce perinatal psychopathology in birthing parents in England. [PDF]

BMJ Open
Wang J, Rosan C, Alyousefi-van Dijk K, Darwin Z, Babalis D, Cornelius V, Waddingham E, Richards L, Pilling S, Fearon P, Fonagy P, Pizzo E.   +11 more
europepmc   +1 more source

Cost-effectiveness analysis of inavolisib combined with palbociclib plus fulvestrant in PIK3CA-mutated HR+/Her2- advanced breast cancer in China. [PDF]

Front Pharmacol
Huang W, Li C, Huang Y, Wang C, Zhang Y, Lin Y.   +5 more
europepmc   +1 more source

[055]ICER Newsletter

[055]ICER Newsletter
[REPORT]「デジタルを活用した大学・高専教育高度化プラン」取組②のご紹介 / [全学FD講習会開催報告]「電子教材著作権講習会」「電子教材開発者向け講習会」 / [ICERビデオ班より ...
openaire  

Phosphorylation deficient inducible cAMP early repressor (ICER) modulates tumorigenesis and survival in a transgenic zebrafish (Danio rerio) model of melanoma

Biology Open
Justin Wheelan, Melissa Spigelman, Angelo Cirinelli, James Reilly, Carlos A. Molina   +4 more
doaj   +1 more source

Risk stratification using coronary artery calcium and potential benefit of semaglutide therapy: A cost-effectiveness modelling study. [PDF]

Diabetes Obes Metab
Ponnana SR, Zhang T, Sirasapalli SK, Chen Z, Dazard JE, Surya N, Elhussain S, Sivanantham K, Okyere R, Neeland IJ, Rajagopalan S, Deo SV.   +11 more
europepmc   +1 more source

[056]ICER Newsletter

[056]ICER Newsletter
教材開発センターの取り組み[岡田義広センター長] / 講義等ビデオの撮影・編集・公開 : ご依頼下さい / ICT活用対話型電子副教材の開発と支援 : ご依頼下さい / 「電子教材著作権講習会」と「電子教材開発者向け講習会」 : ご依頼下さい / 退任教員のご紹介[大井 京 准教授/石 偉 助教]
openaire  

First-line enfortumab vedotin-pembrolizumab versus nivolumab plus gemcitabine-cisplatin in metastatic urothelial cancer: a cost-effectiveness study. [PDF]

Front Public Health
Ying H, Fu B.
europepmc   +1 more source